Recently Featured

Serif, Flagship’s Latest Biotech, Aims to Revolutionize Genetic Medicine with Modified DNA Therapies

April 30, 2026
Serif, a new biotech startup under Flagship Pioneering, is advancing the field of genetic medicine with its innovative approach to developing “modified DNA” therapies. This novel technology seeks to integrate the advantages of various therapeutic modalities, including messenger RNA and traditional gene therapy, to create a more effective treatment paradigm. As the demand for personalized…

Eli Lilly doubles down on in vivo with $7bn Kelonia buyout

April 30, 2026
Eli Lilly has made a significant move in the biopharmaceutical landscape by acquiring Kelonia for $7 billion, enhancing its capabilities in in vivo gene therapy. This acquisition provides Lilly with a robust lentiviral and lipid nanoparticle (LNP)-based platform for in vivo delivery, positioning the company to capitalize on the growing demand for advanced gene therapies.…

AstraZeneca Eyes 5th Ultomiris Indication After Kidney Disease Trial Win

April 30, 2026
AstraZeneca has announced a significant milestone in its development of Ultomiris, revealing that a Phase 3 trial for the rare kidney disease IgA nephropathy (IgAN) demonstrated a clinically meaningful and statistically significant reduction in urinary protein levels after 34 weeks of treatment. This promising outcome not only highlights the therapeutic potential of Ultomiris but also…

Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy

April 30, 2026
Pfizer and Astellas have achieved a significant milestone with the FDA’s acceptance for priority review of their supplemental Biologics License Application (sBLA) concerning the perioperative use of Padcev in combination with Keytruda for the treatment of muscle-invasive bladder cancer (MIBC). This expedited review status underscores the FDA’s recognition of the potential benefits this therapy may…

Ongoing Cases